functional analysis of CD200 for colorectal cancer cell

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18161
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Nara Medical University
• Principal Investigator: Iwasa Yosuke 奈良県立医科大学, 医学部附属病院, 研究員 (30812317)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 大腸癌 / CD200

Outline of Final Research Achievements

In the treatment of colorectal cancer, chemotherapy and molecular-targeted therapy contribute to improved prognosis. CD200 is related to B7 family, and has been shown to be an important role in immunoregulation, and has been reported to be the prognostic factor in several cancer cells, such as leukemia.
We examined rectal cancer patients who underwent rectal resection. Resected specimen were analyzed for CD200 expression by immunohistochemistry. In univariate analysis, CD200 high score group is significant poor prognostic factor, and multivariate analysis, CD200 high score group is independent prognostic factor. Furthermore, CD200 expression might be associated with liver and lung metastasis.

Free Research Field

消化器外科

Academic Significance and Societal Importance of the Research Achievements

大腸癌の治療は進歩し予後は向上してきているが，さらなる予後向上のためには新たな治療法の開発が望まれる．免疫療法が臨床応用されてきているが，大腸癌患者において現状恩恵を受ける患者は限定される．CD200も免疫回避機構を有すると報告がされていること，また，今回の結果から何らかの化学療法抵抗性に関与している可能性があり，今後さらなる機能解析が進むことで，新たな癌治療薬として臨床応用されることが期待される．